Ensysce Biosciences develops an abuse-deterrent and overdose technology that can be applied to 75% of all marketed drugs.
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the company is in the process of developing a new class of tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 6, 2012 | Series Unknown | $1M | 1 | Texas Wide Open for Business | — | Detail |
Jun 10, 2010 | Series A | $1.50M | 1 | Texas Wide Open for Business | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Texas Wide Open for Business | Yes | Series Unknown |